Topic: autoimmune disease
Pfizer has set up a new partnering network to try to foster collaborations with top-tier universities
Just over a year ago Syntimmune announced Boehringer and Pfizer veteran David de Graaf, Ph.D., as its new CEO. Now he’s out the door.
The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.
Ionis Pharmaceuticals has signed the rights to a second antisense drug over to Janssen for a fee of $5 million.
Cancer and autoimmune startup Cue Biopharma has ended the year with a potentially lucrative new deal with Merck.
A University of Edinburgh-led team has uncovered a mechanism in MS that prevents regulatory T cells—which prevent autoimmune activity—from developing.
The series D follows fast after InflaRx established the potential of its anti-human complement factor C5a monoclonal antibody IFX-1 with phase 2 data.
Just months after its $80 million IPO, AnaptysBio is looking to raise another block of cash and accelerate development of its lead drug for eczema.
Celgene has secured an option on two preclinical assets in development at Nimbus Therapeutics, including a TYK2 inhibitor.
With some tweaks, a gene therapy delivered to the liver could become a new treatment for multiple sclerosis.